Pharsight

Arnuity Ellipta generic

Arnuity Ellipta is an inhalable powder owned by Glaxosmithkline. The active ingredient of this drug is fluticasone furoate. Arnuity Ellipta was first authorized for market use on August 20, 2014, and holds a total of 11 patents.

When will Arnuity Ellipta generic be available?

Generic Arnuity Ellipta may become available after the expiration of the last patent on April 11, 2031. Therefore, generic alternatives for this drug could potentially enter the market after this date.

Arnuity Ellipta uses

Arnuity Ellipta is primarily used for the treatment of asthma. The effectiveness of the treatment comes from the active ingredient fluticasone furoate, a corticosteroid that helps to reduce inflammation in the lungs and ease breathing.

Arnuity Ellipta patent expiration

Arnuity Ellipta has a multitude of patents, each for an individual aspect of the drug, such as the medicament dispenser and manifold. The expiration dates of these patents range between 2027 and 2031, with the last one set to expire on April 11, 2031. Keep an eye out for the generic Arnuity Ellipta after this date. Below are the details of the patent:

EPO Oppostions filed on Arnuity Ellipta

Arnuity Ellipta dosage

Want to ask something?